FY2026 EPS Estimates for FATE Decreased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has decreased its FY2026 earnings estimate for Fate Therapeutics from ($0.73) to ($0.93) per share, reflecting a bearish outlook for the biopharmaceutical company's financial performance.
• Fate Therapeutics' stock price recently opened at $1.11, with a 12-month low of $0.6611 and a high of $4.20, indicating significant volatility within the year.
• The consensus rating for Fate Therapeutics among analysts is a "Hold," with a target price set at $3.30, as several analysts have issued mixed ratings on the stock.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2026 earnings estimates for shares of Fate Therapeutics in a note issued to investors on Wednesday, August 20th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will earn ($0.93) per share for the year, down from their prior forecast of ($0.73). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share.

A number of other equities analysts also recently issued reports on FATE. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Robert W. Baird dropped their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Barclays cut their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wells Fargo & Company decreased their price objective on shares of Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating for the company in a research note on Wednesday, August 13th. Finally, Wall Street Zen upgraded Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $3.30.

Fate Therapeutics Stock Down 1.8%

Shares of NASDAQ:FATE opened at $1.11 on Friday. The business's 50 day moving average is $1.13 and its 200 day moving average is $1.14. Fate Therapeutics has a 12-month low of $0.6611 and a 12-month high of $4.20. The stock has a market cap of $128.02 million, a price-to-earnings ratio of -0.77 and a beta of 2.24.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%.The firm had revenue of $1.91 million during the quarter, compared to analyst estimates of $1.16 million.

Institutional Investors Weigh In On Fate Therapeutics

Large investors have recently modified their holdings of the stock. Graham Capital Management L.P. bought a new position in Fate Therapeutics during the fourth quarter valued at $37,000. Savant Capital LLC purchased a new position in shares of Fate Therapeutics during the 2nd quarter valued at $27,000. Brevan Howard Capital Management LP bought a new position in shares of Fate Therapeutics during the 4th quarter worth $41,000. Bridgeway Capital Management LLC bought a new position in shares of Fate Therapeutics during the 2nd quarter worth $28,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Fate Therapeutics in the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 97.54% of the company's stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.